Foamix Pharmaceuticals to Present at Jefferies London Healthcare Conference on November 17

REHOVOT, Israel and BRIDGEWATER, New Jersey, Nov. 10, 2016 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dr. Dov Tamarkin, CEO, will provide a corporate overview at Jefferies London Healthcare Conference, being held at the Waldorf Hilton Hotel in London, UK, November 16-17, 2016.

About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological conditions. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Mylan.

For more information, please visit www.foamixpharma.com.

Contact:                                               
Dorit Hayon
Foamix Pharmaceuticals Ltd.
+972-8-9316233
[email protected]                                

US Investor Relations
Michael Rice
LifeSci Advisors, LLC
+1-646-597-6979
[email protected]

Logo: http://photos.prnewswire.com/prnh/20160906/404614LOGO

SOURCE Foamix Pharmaceuticals Ltd